Eugene Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eugene Wong has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lock
London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 5W9, Canada
4 shared publications Jeff Chen
Physics & Engineering, London Regional Cancer Program, Canada; Department of Oncology, University of Western Ontario, London, Canada; Department of Medical Biophysics, University of Western Ontario, London, Canada
3 shared publications- Michael D. Jensen
Department of Medical Biophysics, The University of Western Ontario, 1151 Richmond Street, London, Ontario N6A 3K7, Canada
3 shared publications - Paula J. Foster
Cellular and Molecular Imaging Group, Robarts Research Institute, London, ON, Canada
3 shared publications Abdulla Elsaleh
Department of Physics and Astronomy, Western University, Canada
2 shared publications- Ann F. Chambers
Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
2 shared publications
Latest Publications
- 8 May 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 72 (11) , 3350-3358
Electrode Design for Internal Electric Field Delivery to Brain Tumors: Considering Electrical Power and Dynamic Field Shaping
Objective: Brain cancer treatment using low intensity electrotherapy techniques is gaining interest. Localized electric field delivery via an implanted array of electrodes, termed Intratumoral Modulation Therapy (IMT), was found efficacious against brain cancers preclinically. With prior IMT studies supporting the transition towards patient application, we consider optimizing the design of electrodes, such that power consumption is minimized while retaining tumor field coverage and field shaping capability. Methods: Cylindrical multi-contact electrodes were modelled with variable radius, spacing between contacts and contact length, and applied to spherical tumors ranging from 20–40 mm in diameter. Stimulation programming was optimized and the overall power analyzed for each design such that target coverage was maintained. To investigate the field shaping potential, designs were further optimized on 11 glioma patient MR images with irregular shaped tumors. Results: The IMT electrode parameters found to minimize power consumption were maximal electrode radius (0.8 mm) and minimal contact spacing (1 mm). Analysis of treatment plans on patient images found 4 mm contact length to minimize complexity (total number of contacts) while maintaining field shaping capability. Conclusion: In this study, electrodes were designed specifically for IMT that minimized power consumption while maintaining field coverage and shaping. This design was robust in its applicability to patient samples. Significance: Due to the complexity of dynamic IMT electric field delivery, the established planning system and the custom IMT hardware designed in this study are necessary precursors to human applications. With this work we are one step closer to treating patients with brain cancer.
- 8 May 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Biomedical Engineering
- Vol. 72 (11) , 3350-3358
Electrode Design for Internal Electric Field Delivery to Brain Tumors: Considering Electrical Power and Dynamic Field Shaping
Objective: Brain cancer treatment using low intensity electrotherapy techniques is gaining interest. Localized electric field delivery via an implanted array of electrodes, termed Intratumoral Modulation Therapy (IMT), was found efficacious against brain cancers preclinically. With prior IMT studies supporting the transition towards patient application, we consider optimizing the design of electrodes, such that power consumption is minimized while retaining tumor field coverage and field shaping capability. Methods: Cylindrical multi-contact electrodes were modelled with variable radius, spacing between contacts and contact length, and applied to spherical tumors ranging from 20–40 mm in diameter. Stimulation programming was optimized and the overall power analyzed for each design such that target coverage was maintained. To investigate the field shaping potential, designs were further optimized on 11 glioma patient MR images with irregular shaped tumors. Results: The IMT electrode parameters found to minimize power consumption were maximal electrode radius (0.8 mm) and minimal contact spacing (1 mm). Analysis of treatment plans on patient images found 4 mm contact length to minimize complexity (total number of contacts) while maintaining field shaping capability. Conclusion: In this study, electrodes were designed specifically for IMT that minimized power consumption while maintaining field coverage and shaping. This design was robust in its applicability to patient samples. Significance: Due to the complexity of dynamic IMT electric field delivery, the established planning system and the custom IMT hardware designed in this study are necessary precursors to human applications. With this work we are one step closer to treating patients with brain cancer.
- Open Access
- 29 September 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (10) , 5862-5872
Prognostic Index for Liver Radiation (PILiR)
A Prognostic Index for Liver Radiation (PILiR) for improved patient selection for stereotactic liver-directed radiotherapy (SBRT) was developed. Using a large single-center database, 195 patients treated with SBRT for local control, including 66 with hepatocellular carcinoma (HCC) and 129 with metastatic liver disease, were analyzed. Only patients ineligible for alternative treatments were included. Overall survival was 11.9 months and 9.4 months in the HCC group and metastatic groups, respectively. In the combined dataset, Child–Pugh Score (CPS) (p = 0.002), serum albumin (p = 0.039), and presence of extrahepatic disease (p = 0.012) were significant predictors of early death on multivariable analysis and were included in the PILiR (total score 0 to 5). Median survival was 23.8, 9.1, 4.5, and 2.6 months for patients with 0, 1–2, 3, and 4–5 points, respectively. In the HCC dataset, CPS (p < 0.001) and gross tumor volume (p = 0.013) were predictive of early death. In the metastatic dataset, serum albumin (p < 0.001) and primary disease site (p = 0.003) were predictive of early death. The AUC for the combined, HCC, and metastatic datasets are 0.78, 0.84, and 0.80, respectively. Poor liver function (defined by CPS and serum albumin) and extrahepatic disease were most predictive of early death, providing clinically important expected survival information for patients and caregivers.
- 29 September 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (10) , 5862-5872
Open AccessPrognostic Index for Liver Radiation (PILiR)
A Prognostic Index for Liver Radiation (PILiR) for improved patient selection for stereotactic liver-directed radiotherapy (SBRT) was developed. Using a large single-center database, 195 patients treated with SBRT for local control, including 66 with hepatocellular carcinoma (HCC) and 129 with metastatic liver disease, were analyzed. Only patients ineligible for alternative treatments were included. Overall survival was 11.9 months and 9.4 months in the HCC group and metastatic groups, respectively. In the combined dataset, Child–Pugh Score (CPS) (p = 0.002), serum albumin (p = 0.039), and presence of extrahepatic disease (p = 0.012) were significant predictors of early death on multivariable analysis and were included in the PILiR (total score 0 to 5). Median survival was 23.8, 9.1, 4.5, and 2.6 months for patients with 0, 1–2, 3, and 4–5 points, respectively. In the HCC dataset, CPS (p < 0.001) and gross tumor volume (p = 0.013) were predictive of early death. In the metastatic dataset, serum albumin (p < 0.001) and primary disease site (p = 0.003) were predictive of early death. The AUC for the combined, HCC, and metastatic datasets are 0.78, 0.84, and 0.80, respectively. Poor liver function (defined by CPS and serum albumin) and extrahepatic disease were most predictive of early death, providing clinically important expected survival information for patients and caregivers.
- Open Access
- 20 August 2024
- Published by MDPI AG in Preprints.org
Prognostic Index for Liver Radiation (PILiR)
A Clinical Prognostic Index (CPI) for improved patient selection for stereotactic liver-directed radiotherapy (SBRT) was developed. Using a large single-center database, 195 patients treated with SBRT for local control, including 66 with hepatocellular carcinoma (HCC) and 129 with metastatic liver disease, were analyzed. Only patients ineligible for alternative treatments were included. Overall survival was 11.9 months and 9.4 months in the HCC group and metastatic groups, respectively. In the combined dataset, Child-Pugh Score (CPS) (p=0.002), serum albumin (p=0.039) and presence of extrahepatic disease (p=0.012) were significant predictors of early death on multivariable analysis and were included in the CPI (total score 0 to 5). Median survival was 23.8, 9.1, 4.5 and 2.6 months for patients with 0, 1-2, 3 and 4-5 points, respectively. In the HCC dataset, CPS (p<0.001) and gross tumor volume (p=0.013) were predictive of early death. In the metastatic dataset, serum albumin (p<0.001) and primary disease site (p=0.003) were predictive of early death. The AUC for the combined, HCC, and metastatic datasets are 0.78, 0.84, 0.80 respectively. Poor liver function (defined by CPS and serum albumin) and extrahepatic disease were most predictive of early death, providing clinically important expected survival information for patients and caregivers.
- 20 August 2024
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Index for Liver Radiation (PILiR)
A Clinical Prognostic Index (CPI) for improved patient selection for stereotactic liver-directed radiotherapy (SBRT) was developed. Using a large single-center database, 195 patients treated with SBRT for local control, including 66 with hepatocellular carcinoma (HCC) and 129 with metastatic liver disease, were analyzed. Only patients ineligible for alternative treatments were included. Overall survival was 11.9 months and 9.4 months in the HCC group and metastatic groups, respectively. In the combined dataset, Child-Pugh Score (CPS) (p=0.002), serum albumin (p=0.039) and presence of extrahepatic disease (p=0.012) were significant predictors of early death on multivariable analysis and were included in the CPI (total score 0 to 5). Median survival was 23.8, 9.1, 4.5 and 2.6 months for patients with 0, 1-2, 3 and 4-5 points, respectively. In the HCC dataset, CPS (p<0.001) and gross tumor volume (p=0.013) were predictive of early death. In the metastatic dataset, serum albumin (p<0.001) and primary disease site (p=0.003) were predictive of early death. The AUC for the combined, HCC, and metastatic datasets are 0.78, 0.84, 0.80 respectively. Poor liver function (defined by CPS and serum albumin) and extrahepatic disease were most predictive of early death, providing clinically important expected survival information for patients and caregivers.
- Open Access
- 5 April 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (8) , 085012
Spatiotemporally dynamic electric fields for brain cancer treatment: an in vitro investigation
Objective . The treatment of glioblastoma (GBM) using low intensity electric fields (∼1 V cm −1 ) is being investigated using multiple implanted bioelectrodes, which was termed intratumoral modulation therapy (IMT). Previous IMT studies theoretically optimized treatment parameters to maximize coverage with rotating fields, which required experimental investigation. In this study, we employed computer simulations to generate spatiotemporally dynamic electric fields, designed and purpose-built an IMT device for in vitro experiments, and evaluated the human GBM cellular responses to these fields. Approach . After measuring the electrical conductivity of the in vitro culturing medium, we designed experiments to evaluate the efficacy of various spatiotemporally dynamic fields: (a) different rotating field magnitudes, (b) rotating versus non-rotating fields, (c) 200 kHz versus 10 kHz stimulation, and (d) constructive versus destructive interference. A custom printed circuit board (PCB) was fabricated to enable four-electrode IMT in a 24-well plate. Patient derived GBM cells were treated and analyzed for viability using bioluminescence imaging. Main results . The optimal PCB design had electrodes placed 6.3 mm from the center. Spatiotemporally dynamic IMT fields at magnitudes of 1, 1.5, and 2 V cm −1 reduced GBM cell viability to 58%, 37% and 2% of sham controls respectively. Rotating versus non-rotating, and 200 kHz versus 10 kHz fields showed no statistical difference. The rotating configuration yielded a significant reduction ( p < 0.01) in cell viability (47 ± 4%) compared to the voltage matched (99 ± 2%) and power matched (66 ± 3%) destructive interference cases. Significance . We found the most important factors in GBM cell susceptibility to IMT are electric field strength and homogeneity. Spatiotemporally dynamic electric fields have been evaluated in this study, where improvements to electric field coverage with lower power consumption and minimal field cancellations has been demonstrated. The impact of this optimized paradigm on cell susceptibility justifies its future use in preclinical and clinical trial investigations.
- 5 April 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (8) , 085012
Open AccessSpatiotemporally dynamic electric fields for brain cancer treatment: an in vitro investigation
Objective . The treatment of glioblastoma (GBM) using low intensity electric fields (∼1 V cm −1 ) is being investigated using multiple implanted bioelectrodes, which was termed intratumoral modulation therapy (IMT). Previous IMT studies theoretically optimized treatment parameters to maximize coverage with rotating fields, which required experimental investigation. In this study, we employed computer simulations to generate spatiotemporally dynamic electric fields, designed and purpose-built an IMT device for in vitro experiments, and evaluated the human GBM cellular responses to these fields. Approach . After measuring the electrical conductivity of the in vitro culturing medium, we designed experiments to evaluate the efficacy of various spatiotemporally dynamic fields: (a) different rotating field magnitudes, (b) rotating versus non-rotating fields, (c) 200 kHz versus 10 kHz stimulation, and (d) constructive versus destructive interference. A custom printed circuit board (PCB) was fabricated to enable four-electrode IMT in a 24-well plate. Patient derived GBM cells were treated and analyzed for viability using bioluminescence imaging. Main results . The optimal PCB design had electrodes placed 6.3 mm from the center. Spatiotemporally dynamic IMT fields at magnitudes of 1, 1.5, and 2 V cm −1 reduced GBM cell viability to 58%, 37% and 2% of sham controls respectively. Rotating versus non-rotating, and 200 kHz versus 10 kHz fields showed no statistical difference. The rotating configuration yielded a significant reduction ( p < 0.01) in cell viability (47 ± 4%) compared to the voltage matched (99 ± 2%) and power matched (66 ± 3%) destructive interference cases. Significance . We found the most important factors in GBM cell susceptibility to IMT are electric field strength and homogeneity. Spatiotemporally dynamic electric fields have been evaluated in this study, where improvements to electric field coverage with lower power consumption and minimal field cancellations has been demonstrated. The impact of this optimized paradigm on cell susceptibility justifies its future use in preclinical and clinical trial investigations.
- Open Access
- 1 March 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 21, 115-122
Glial activation positron emission tomography imaging in radiation treatment of breast cancer brain metastases
- 1 March 2022
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 21, 115-122
Open AccessGlial activation positron emission tomography imaging in radiation treatment of breast cancer brain metastases
- 1 January 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 169, 103566
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
- 1 January 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 169, 103566
Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications
- Open Access
- 1 June 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 104
Half brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response
Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases.
- 1 June 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13 (1) , 104
Open AccessHalf brain irradiation in a murine model of breast cancer brain metastasis: magnetic resonance imaging and histological assessments of dose-response
Brain metastasis is becoming increasingly prevalent in breast cancer due to improved extra-cranial disease control. With emerging availability of modern image-guided radiation platforms, mouse models of brain metastases and small animal magnetic resonance imaging (MRI), we examined brain metastases’ responses from radiotherapy in the pre-clinical setting. In this study, we employed half brain irradiation to reduce inter-subject variability in metastases dose-response evaluations. Half brain irradiation was performed on a micro-CT/RT system in a human breast cancer (MDA-MB-231-BR) brain metastasis mouse model. Radiation induced DNA double stranded breaks in tumors and normal mouse brain tissue were quantified using γ-H2AX immunohistochemistry at 30 min (acute) and 11 days (longitudinal) after half-brain treatment for doses of 8, 16 and 24 Gy. In addition, tumor responses were assessed volumetrically with in-vivo longitudinal MRI and histologically for tumor cell density and nuclear size. In the acute setting, γ-H2AX staining in tumors saturated at higher doses while normal mouse brain tissue continued to increase linearly in the phosphorylation of H2AX. While γ-H2AX fluorescence intensities returned to the background level in the brain 11 days after treatment, the residual γ-H2AX phosphorylation in the radiated tumors remained elevated compared to un-irradiated contralateral tumors. With radiation, MRI-derived relative tumor growth was significantly reduced compared to the un-irradiated side. While there was no difference in MRI tumor volume growth between 16 and 24 Gy, there was a significant reduction in tumor cell density from histology with increasing dose. In the longitudinal study, nuclear size in the residual tumor cells increased significantly as the radiation dose was increased. Radiation damages to the DNAs in the normal brain parenchyma are resolved over time, but remain unrepaired in the treated tumors. Furthermore, there is a radiation dose response in nuclear size of surviving tumor cells. Increase in nuclear size together with unrepaired DNA damage indicated that the surviving tumor cells post radiation had continued to progress in the cell cycle with DNA replication, but failed cytokinesis. Half brain irradiation provides efficient evaluation of dose-response for cancer cell lines, a pre-requisite to perform experiments to understand radio-resistance in brain metastases.
- Open Access
- 1 June 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (3) , 219-227
Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment
- 1 June 2016
- Published by Elsevier in Translational Oncology
- Vol. 9 (3) , 219-227
Open AccessEvaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment
- 1 May 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (2) , 331-336
Evaluation of unified intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer
- 1 May 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (2) , 331-336
Evaluation of unified intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer
- 1 March 2016
- Published by Elsevier in Brachytherapy
- Vol. 15 (2) , 231-239
Three-dimensional transrectal ultrasound guided high-dose-rate prostate brachytherapy: A comparison of needle segmentation accuracy with two-dimensional image guidance
- 1 March 2016
- Published by Elsevier in Brachytherapy
- Vol. 15 (2) , 231-239
Three-dimensional transrectal ultrasound guided high-dose-rate prostate brachytherapy: A comparison of needle segmentation accuracy with two-dimensional image guidance